Orchid Pharma: NCLT Dismisses DBS Bank's CIRP Lease Rent Claim, No Financial Impact

The National Company Law Tribunal (NCLT), Chennai Bench, on April 2, 2026, dismissed an application filed by DBS Bank (formerly Lakshmi Vilas Bank).
This order, made available on April 10, 2026, concerned claims for lease rent during the Corporate Insolvency Resolution Process (CIRP).

Reader Takeaway: NCLT clarity on CIRP lease claims; company confirms zero financial impact.

What just happened (today’s filing)

The National Company Law Tribunal (NCLT), Chennai Bench, has issued an order dismissing an application from DBS Bank (formerly Lakshmi Vilas Bank).

The application pertained to claims for lease rent during the company's Corporate Insolvency Resolution Process (CIRP) period.

Orchid Pharma has explicitly stated that the NCLT's order regarding the DBS Bank's claim has no financial impact on the company.

Why this matters

Resolving claims related to the CIRP period is crucial for providing finality to past liabilities. The dismissal by the NCLT offers a degree of legal clarity for Orchid Pharma.

The backstory (grounded)

Orchid Pharma, a Chennai-based pharmaceutical manufacturer, underwent a significant Corporate Insolvency Resolution Process (CIRP) that commenced in August 2017. The company had accumulated substantial debt, reportedly around ₹3,200-3,600 crore, making its revival a complex legal and financial undertaking. After a lengthy process involving multiple resolution applicants and legal challenges, including interventions by the NCLAT and Supreme Court, Dhanuka Laboratories' resolution plan was approved and implemented around March 2020. In parallel, the company had also been engaged in resolving other disputes, including a previously settled lease rental matter with DBS Bank through a compromise.

What changes now

• Shareholders gain increased certainty regarding past liabilities related to the CIRP period.
• The dismissal removes a potential point of contention that could have led to further financial claims.
• It reinforces the company's position on managing liabilities post-CIRP resolution.

Risks to watch

While this specific NCLT order has been deemed to have no financial impact, general legal and regulatory landscapes always warrant monitoring for companies.

Peer comparison

Other pharmaceutical companies like Sterling Biotech Ltd and Parental Drugs India Ltd have also navigated complex insolvency resolution processes, highlighting the sector's challenges and recovery paths through CIRP.

Context metrics (time-bound)

N/A

What to track next

• Any potential for DBS Bank to pursue further legal avenues regarding this specific dismissal.
• Continued operational performance and financial health of Orchid Pharma post-resolution.
• Any further developments related to past legal proceedings or claims.